Harvard Bioscience - צמיחת מכירות משנה לשנה (TTM) HBIO

The TTM revenue growth for Harvard Bioscience (HBIO) demonstrates the impact of assembly and logistics outsourcing on operational flows. Government scientific grants support business resilience, while the 2.30 metric serves as the target level. Jim Green's strategy to refresh the product portfolio and expand margins ensures price stability, smoothing out the market volatility shown on this chart.
Harvard Bioscience, Inc. - פילוחים אנליטיים ומדדי מפתח (HBIO)

This indicator reflects the revenue growth rate over the last twelve months relative to the preceding year. The calculation algorithm identifies systemic business degradation or development, neutralizing seasonality through a rolling period. By analyzing the annual sales revenue growth over a rolling period, an investor assesses the company's actual expansion speed. For Harvard Bioscience (HBIO), this metric signals demand sensitivity to the capital expenditures of pharmaceutical laboratories. A decline in the chart's momentum would indicate a need for strict cost control despite stable financial resilience.